No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents

Expert Opinion on Drug Safety

Volumn 15, Issue 12, 2016, Pages 1653-1659

  Chiricozzi, Andrea ^a   Romanelli, Marco ^a   Saraceno, Rosita ^b   Torres, Tiago ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Brodalumab; depression; IL 17; ixekizumab; psoriasis; secukinumab; suicide

Indexed keywords

BRODALUMAB; INTERLEUKIN 17; IXEKIZUMAB; SECUKINUMAB; IL17A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

DEPRESSION; DRUG SAFETY; DRUG USE; HUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; ANIMAL; ANTAGONISTS AND INHIBITORS; STATISTICS AND NUMERICAL DATA; SUICIDE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-17; PSORIASIS; SUICIDE;

EID: 84996479960     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1228872     Document Type: Review

References (52)

1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
2. Jensen P, Ahlehoff O, Egeberg A, et al. Psoriasis and new-onset depression:a Danish nationwide cohort study. Acta Derm Venereol. 2016;96:39–42.
3. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis:a population-based cohort study. Arch Dermatol. 2010;146:891–895.
4. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases:a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984–991.
5. Egeberg A, Hansen PR, Gislason GH, et al. Risk of self-harm and non-fatal suicide attempts, and completed suicide in patients with psoriasis - a population-based cohort study. Br J Dermatol. 2016 Apr 1. [Epub ahead of print]. DOI:10.1111/bjd.14633
6. Allison DJ, Ditor DS., The common inflammatory etiology of depression and cognitive impairment:a therapeutic target. J Neuroinflammation. 2014;11:151.• Evidence linking inflammation to neuronal impairment.
7. Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression:when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.• Overview about the role of inflammation in psychiatric disorders.
8. Han Q-Q, Yu J. Inflammation:a mechanism of depression? Neurosci Bull. 2014;30:515–523.• Overview about the role of inflammation in psychiatric disorders.
9. Raison CL, Capuron L, Miller AH. Cytokines sing the blues:inflammation and the pathogenesis of major depression. Trend Immunol. 2006;27:24–31.• Overview about the role of inflammation in psychiatric disorders.
10. Miller AH, Maletic V, Raison CL. Inflammation and its discontents:the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732.741.• Overview about the role of inflammation in psychiatric disorders.
11. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to severe psoriasis:results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457–465.
12. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis:double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.
13. Roblin X, Oltean P, Heluwaert F, et al. Panic attack with suicide:an exceptional ad- verse effect of infliximab. Dig Dis Sci. 2006;51:1056.
14. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gas Troenterol. 2000;95:3490–3497.
15. Papp KA, Reich K, Paul C, et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Feb 23. [Epub ahead of print]. DOI:10.1111/bjd.14493
16. Capuron L, Miller AH. Immune system to brain signaling:neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–238.
17. Beurel E, Harrington LE, Jope RS. Inflammatory Th17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013;73:622–630.
18. Swardfager W, Herrmann N, Andreazza AC, et al. Poststroke neuropsychiatric symptoms:relationships with IL-17 and oxidative stress. Biomed Res Int. 2014;2014:245210.
19. Liu Q, Xin W, He P, et al. Interleukin-17 inhibits adult hippocampal neurogenesis. Sci Rep. 2014;19(4):7554.
20. Kleinschek MA, Owyang AM, Joyce-Shaikh B, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204:161–70.E.
21. Bartlett HS, Million RP. Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015;14:11–12.
22. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htmX
23. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003729/smops/Positive/human_smop_000755.jsp&mid=WC0b01ac058001d127X
24. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htmX
25. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003943/smops/Positive/human_smop_000937.jsp&mid=WC0b01ac058001d127X
26. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43:402–407.
27. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor:implications for signal transduction and therapy. Cytokine. 2008;41:92–104.• A comprehensive overview about signaling of IL-17 family cytokines.
28. Available from:https://www.drugs.com/nda/brodalumab_160719.html.•• Latest update on brodalumab approval process by FDA.
29. Available from:http://www.medscape.com/viewarticle/866406?nlid=108537_1585&src=WNL_mdplsfeat_160726_mscpedit_derm&uac=208695CJ&spon=33&impID=1166274&faf=1•• Latest update on brodalumab approval process by FDA.
30. Sanford M, McKeage K. Secukinumab:first global approval. Drugs. 2015;75:329–338.
31. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
32. Augustin M, Abeysinghe S, Mallya U, et al. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016;30:645–649.
33. van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience:a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.
34. Markham A. Ixekizumab:first global approval. Drugs. 2016;76:901–905.
35. Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis:results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–1219.
36. Strober B, Papp K, Leonardi C, et al. Integrated safety of ixekizumab in patients with moderate-to-severe Psoriasis:results from a pooled analysis of 7 clinical trials [abstract no. 3101]. 74th Annual Meeting; 2016 March 4–8; Washington (DC).
37. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
38. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–1190.e3.
39. Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life:use of a novel patient-reported outcome measure, the Psoriasis symptom inventory. Br J Dermatol. 2014;170:705–715.•• This study showed the positive impact of brodalumab on quality of life and depression.
40. Umezawa Y, Nakagawa H, Niiro H, et al. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016 Jun 29. [Epub ahead of print]. DOI:10.1111/jdv.13785
41. Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis:results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. [Poster 275]. 74th Annual Meeting; 2016 March 4–8; Washington (DC).
42. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.• Phase III studies showing superior brodalumab efficacy in treating psoriasis compared to ustekinumab.
43. Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of Psoriasis:a review of phase III trials. Dermatol Ther (Heidelb). 2016;6:111–124.• Comprehensive review on clinical outcomes deriving from brodalumab phase III program.
44. Strober B, Langley R, Blicharsk T. AMAGINE-3:a phase 3 study of efficacy and safety of brodalumab compared with Placebo and Ustekinumab in moderate to severe plaque psoriasis patients. [Poster 1146].74th Annual Meeting; 2016 March 4–8; Washington (DC).
45. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis:CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.• Phase III study showing superior secukinumab efficacy in treating psoriasis compared to ustekinumab.
46. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3):results from two phase 3 randomised trials. Lancet. 2015;386:541–551.• Phase III studies showing superior ixekizumab efficacy in treating psoriasis compared to etanercept.
47. Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(Suppl 1):9–20.
48. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993–1005.
49. Available from:http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5701
50. Schmidt C. Suicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015;33:894–895.•• Highly relevant papers discussing potential confounding factors and pathogenic links related to suicide behavior and IL-17 signaling blockade.
51. Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190–192.•• Critical paper on suicide behavior and brodalumab use.
52. Celgene Corporation. Highlights of prescribing information. cited July5 2015. Available from:http://www.otezla.com/otezla-prescribinginformation.pdf